Dactinomycin Clinical Trials
4 recruitingBiologic
Phase 33Phase 21
Showing 1–4 of 4 trials
Recruiting
Phase 3
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Stage I Mixed Cell Type Kidney Wilms TumorStage II Mixed Cell Type Kidney Wilms TumorStage III Mixed Cell Type Kidney Wilms Tumor+1 more
Children's Oncology Group1,656 enrolled153 locationsNCT06401330
Recruiting
Phase 3
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Embryonal RhabdomyosarcomaFusion-Negative Alveolar RhabdomyosarcomaSpindle Cell/Sclerosing Rhabdomyosarcoma
Children's Oncology Group205 enrolled179 locationsNCT05304585
Recruiting
Phase 3
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Pleuropulmonary Blastoma
Children's Oncology Group110 enrolled76 locationsNCT06647953
Recruiting
Phase 2
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
Rhabdomyosarcoma
St. Jude Children's Research Hospital135 enrolled3 locationsNCT06023641